Literature DB >> 19542240

Thirst perception and arginine vasopressin production in a kindred with an activating mutation of the type 2 vasopressin receptor: the pathophysiology of nephrogenic syndrome of inappropriate antidiuresis.

S Gupta1, T D Cheetham, H J Lambert, C Roberts, D Bourn, M G Coulthard, S G Ball.   

Abstract

BACKGROUND: Activating mutations of the vasopressin receptor gene on the X chromosome cause the nephrogenic syndrome of inappropriate antidiuresis (NSIAD). We describe a male child who presented with persistent hyponatraemia and whose mother was also found to be hyponatraemic. She had learnt to avoid excess fluid consumption because of associated malaise. Both individuals had a subnormal ability to excrete a water load with mother also demonstrating a heightened sense of thirst at low serum osmolalities.
RESULTS: Mother and child were found to have the previously characterised activating mutation (p.Arg137Cys) of the arginine vasopressin receptor type 2 gene (AVPR2), but had measurable levels of AVP when hyponatraemic.
CONCLUSIONS: We conclude that female carriers of activating mutations of the vasopressin receptor are susceptible to hyponatraemia and therefore need to be provided with advice regarding fluid intake. An altered thirst perception may increase susceptibility to hyponatraemia. We confirm that the presence of measurable amounts of AVP in patients with hyponatraemia does not exclude the diagnosis of NSIAD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19542240     DOI: 10.1530/EJE-09-0246

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  8 in total

1.  The constitutively active V2 receptor mutants conferring NSIAD are weakly sensitive to agonist and antagonist regulation.

Authors:  Julie Tenenbaum; Mohammed A Ayoub; Sanja Perkovska; Anne-Laure Adra-Delenne; Christiane Mendre; Bruno Ranchin; Giamperro Bricca; Ghislaine Geelen; Bernard Mouillac; Thierry Durroux; Denis Morin
Journal:  PLoS One       Date:  2009-12-21       Impact factor: 3.240

Review 2.  Focus on neonatal and infantile onset of nephrogenic syndrome of inappropriate antidiuresis: 12 years later.

Authors:  Flaminia Bardanzellu; Maria Cristina Pintus; Valentina Masile; Vassilios Fanos; Maria Antonietta Marcialis
Journal:  Pediatr Nephrol       Date:  2018-03-15       Impact factor: 3.714

3.  Angiotensin II induces membrane trafficking of natively expressed transient receptor potential vanilloid type 4 channels in hypothalamic 4B cells.

Authors:  Ashwini Saxena; Martha Bachelor; Yong H Park; Flavia R Carreno; T Prashant Nedungadi; J Thomas Cunningham
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-07-30       Impact factor: 3.619

Review 4.  Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment.

Authors:  Hanne B Moeller; Søren Rittig; Robert A Fenton
Journal:  Endocr Rev       Date:  2013-01-29       Impact factor: 19.871

5.  Functional polymorphisms affecting the clinically important arginine-137 residue of AVPR2 do not influence serum sodium concentration at the population level.

Authors:  Yi Fu; Tim Cheetham; David Bourn; Eric Orwoll; David M Cohen
Journal:  Physiol Genomics       Date:  2013-01-29       Impact factor: 3.107

6.  Persistent elevation of urine aquaporin-2 during water loading in a child with nephrogenic syndrome of inappropriate antidiuresis (NSIAD) caused by a R137L mutation in the V2 vasopressin receptor.

Authors:  Clement C Cheung; Melissa A Cadnapaphornchai; Sayali A Ranadive; Stephen E Gitelman; Stephen M Rosenthal
Journal:  Int J Pediatr Endocrinol       Date:  2012-02-10

7.  Nephrogenic syndrome of inappropriate antidiuresis.

Authors:  D Morin; J Tenenbaum; B Ranchin; T Durroux
Journal:  Int J Pediatr       Date:  2012-02-28

8.  Adult female with symptomatic AVPR2-related nephrogenic syndrome of inappropriate antidiuresis (NSIAD).

Authors:  Jennifer Hague; Ruth Casey; Jonathan Bruty; Tom Legerton; Stephen Abbs; Susan Oddy; Andrew S Powlson; Mohamed Majeed; Mark Gurnell; Soo-Mi Park; Helen Simpson
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-02-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.